Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/121085
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Economic evaluation of a nurse-led home and clinic-based secondary prevention programme to prevent progressive cardiac dysfunction in high-risk individuals: the Nurse-led Intervention for Less Chronic Heart Failure (NIL-CHF) randomized controlled study
Author: Maru, S.
Byrnes, J.
Carrington, M.
Chan, Y.-K.
Stewart, S.
Scuffham, P.
Citation: European Journal of Cardiovascular Nursing, 2018; 17(5):439-445
Publisher: European Society of Cardiology
Issue Date: 2018
ISSN: 1474-5151
1873-1953
Statement of
Responsibility: 
Shoko Maru, Joshua Byrnes, Melinda J Carrington, Yih-Kai Chan, Simon Stewart and Paul A Scuffham on behalf of the NIL-CHF Trial Investigators
Abstract: Objective: The objective of this study was to assess the cost-effectiveness of a long-term, nurse-led, multidisciplinary programme of home/clinic visits in preventing progressive cardiac dysfunction in patients at risk of developing de novo chronic heart failure (CHF). Methods: A trial-based analysis was conducted alongside a pragmatic, single-centre, open-label, randomized controlled trial of 611 patients (mean age: 66 years) with subclinical cardiovascular diseases (without CHF) discharged to home from an Australian tertiary referral hospital. A nurse-led home and clinic-based programme (NIL-CHF intervention, n = 301) was compared with standard care (n=310) in terms of life-years, quality-adjusted life-years (QALYs) and healthcare costs. The uncertainty around the incremental cost and QALYs was quantified by bootstrap simulations and displayed on a cost-effectiveness plane. Results: During a median follow-up of 4.2 years, there were no significant between-group differences in life-years (−0.056, p=0.488) and QALYs (−0.072, p=0.399), which were lower in the NIL-CHF group. The NIL-CHF group had slightly lower all-cause hospitalization costs (AUD$2943 per person; p=0.219), cardiovascular-related hospitalization costs (AUD$1142; p=0.592) and a more pronounced reduction in emergency/unplanned hospitalization costs (AUD$4194 per person; p=0.024). When the cost of intervention was added to all-cause, cardiovascular and emergency-related readmissions, the reductions in the NIL-CHF group were AUD$2742 (p=0.313), AUD$941 (p=0.719) and AUD$3993 (p=0.046), respectively. At a willingness-to-pay threshold of AUD$50,000/QALY, the probability of the NIL-CHF intervention being better-valued was 19%. Conclusions: Compared with standard care, the NIL-CHF intervention was not a cost-effective strategy as life-years and QALYs were slightly lower in the NIL-CHF group. However, it was associated with modest reductions in emergency/unplanned readmission costs.
Keywords: NIL-CHF Trial Investigators
Rights: © The European Society of Cardiology 2017.
DOI: 10.1177/1474515117743979
Grant ID: http://purl.org/au-research/grants/nhmrc/519823
Appears in Collections:Aurora harvest 8
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.